Loading…
Loading…
Zacks spotlights Oportun Financial, Uranium Royalty and Amgen, alongside standout gains from its key stock portfolios.
California State Teachers Retirement System grew its position in shares of Thermo Fisher Scientific Inc. (NYSE: TMO) by 49,331.5% in the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 282,654,735 shares of the medical research company's stock after acquiring an additional 282,082,924
Thermo Fisher's growth is gaining momentum as acquisitions strengthen its life sciences reach, but macro risks and competition remain concerns.
Markets wobble heading into the Labor Day weekend as bond vigilantes push back against Washington, oil stays tense with Middle East strikes escalating, and Wall Street analysts make bold calls on names ranging from Broadcom to Moderna that could reshape your portfolio positioning.
Healthcare is moving away from the traditional model of mass-produced, one-size-fits-all treatments toward individualized therapies. This evolution in medicine aims to provide treatments that are not only more effective but also carry a lower risk of adverse side effects by aligning with a patient's unique biology.
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific today announced the launch of the Thermo Scientific™ Multiskan™ Ease Absorbance Microplate Reader, designed to support protein quantification, enzyme-linked immunosorbent assays (ELISAs), cell viability studies, microbial growth monitoring and other routine laboratory applications with simplified operation and dependable performance. Laboratories performing absorbance-based analysis are under increasing pressure to generate reliable data.
Thermo Fisher's EMPAD G2 detector enhances 4D STEM imaging speed, sensitivity and workflow integration, strengthening its Analytical Instruments portfolio.
Beacon Pointe Advisors LLC purchased a new position in Thermo Fisher Scientific Inc. (NYSE: TMO) during the undefined quarter, according to its most recent disclosure with the SEC. The fund purchased 37,709 shares of the medical research company's stock, valued at approximately $18,906,000. Several other hedge funds also recently modified their holdings of